Claims for Patent: 8,927,574

Summary for Patent: 8,927,574

Title:	Crystalline pharmaceutical and methods of preparation and use thereof
Abstract:	Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001##
Inventor(s):	Burnier; John (Pacifica, CA)
Assignee:	SARcode Bioscience Inc. (Brisbane, CA)
Application Number:	13/713,238
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,927,574
Patent Claims:	1. A composition comprising an isolated compound of Formula I: ##STR00020## or a salt thereof, wherein said compound is synthesized according to a method comprising the steps: a) performing base hydrolysis of Formula AA with a base in an aprotic solvent, or performing acid hydrolysis of Formula AA with an acid in an aprotic solvent: ##STR00021## wherein R is a carbon containing moiety; and b) isolating a compound of Formula I or a salt thereof, with an enantiomeric excess of greater than about 90%; wherein said composition has a lower level of residual palladium compared to a composition comprising a compound of Formula I or a salt thereof prepared by palladium-catalyzed transfer hydrogenolysis. 2. The composition of claim 1, wherein the aprotic solvent is dioxane. 3. The composition of claim 1, wherein the base is sodium hydroxide. 4. The composition of claim 1, wherein the acid is hydrogen chloride. 5. The composition of claim 1, wherein R is a substituted or unsubstituted group selected from lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, cyclo(lower)alkenyl, aryl, aralkyl, heterocyclyl, and heteroaryl groups. 6. The composition of claim 1, wherein the residual palladium in the composition is less than about 100 ppm. 7. The composition of claim 1, wherein the residual palladium in the composition is less than about 50 ppm. 8. The composition of claim 1, wherein the residual palladium in the composition is less than about 10 ppm. 9. The composition of claim 1, wherein the residual palladium in the composition is less than about 1 ppm.